The FDA has granted Orphan Drug designation to NS-229 for the treatment of eosinophilic granulomatosis with polyangiitis.

LUND, SE / ACCESS Newswire / May 26, 2025 / Alligator Bioscience (STO:ATORX) - Lund, Sweden - 26 May 2025 - Alligator ...

POLB 001 has been granted FDA orphan drug designation as a preventative therapy for cytokine release syndrome caused by ...

Fast Track Designation is given to drugs that are intended to treat serious conditions and or fill an unmet medical need.

Those with ALS have an average survival of around two to five years from diagnosis, with most ALS patients dying from ...

The author has a $2.75 Price Target on CytoDyn (CYDY) in the Next 6 to 12 months, representing significant upside from its ...

Poolbeg Pharma (AIM: POLB, 'Poolbeg' or the 'Company'), a clinical-stage biopharmaceutical company focussed on the development of innovative medicines to address unmet medical needs, announces that ...

Biopharmaceutical company Poolbeg Pharma said the US Food and Drug Administration has granted Orphan Drug Designation (ODD) ...

Qure divested for $25M, advanced AMT-130 with FDA approvals, and building infrastructure. A strong balance sheet backs ...

U.S. President Donald Trump's trade negotiators are pushing the EU to make unilateral tariff reductions on U.S. goods, saying ...

Glenmark Pharmaceuticals seeks licensing deal for ISB 2001 drug candidate, plans growth with semaglutide in India.

European Commission grants orphan drug designation to Alligator Bioscience’s HLX22 to treat gastric cancer: Lund, Sweden Tuesday, May 27, 2025, 18:00 Hrs [IST] Alligator Bioscie ...